Showing 5971-5980 of 6808 results for "".
- FDA OKS Santalis' Phase 2 Study of EISO For ADhttps://practicaldermatology.com/news/fda-oks-santalis-phase-2-study-of-eiso-in-ad/2458385/The U.S. Food and Drug Administration (FDA) has green lighted Santalis Pharmaceuticals Phase 2 clinical study of East Indian Sandalwood Oil (EISO) cream for the treatment of atopic dermatitis (AD). The multi-center, placebo controlled, double blinded, Phase 2 efficacy and tolerability stu
- Allergan Completes Vitae Tender Offerhttps://practicaldermatology.com/news/allergan-completes-vitae-tender-offer/2458391/Allergan completed their tender offer to purchase all outstanding shares of Vitae Pharmaceuticals, Inc., a clinical-stage biotechnology company. A tender offer occurs when
- Pew Research Gauges Our Attitudes About Cosmetic Surgeryhttps://practicaldermatology.com/news/pew-research-gages-our-attitudes-about-cosmetic-surgery/2458395/New survey data from the Pew Research Center sheds light on American attitudes and beliefs regarding cosmetic surgery. The survey, conducted in
- Study Calls Attention to Negative Impact, Need for Treatment of SKhttps://practicaldermatology.com/news/study-calls-attention-to-negative-impact-need-for-treatment-of-sk/2458393/Patients with asymptomatic seborrheic keratosis (SK) are bothered by highly visible skin lesions and are very interested in treatment to improve their appearance, even if a cost were associated with treatment, according to a new study conducted in dermatology practices by Burke, Inc. on behalf of
- New from NeoStrata: Introducing the ProSystem Retinol Peelhttps://practicaldermatology.com/news/new-from-neostrata-the-prosystem-retinol-peel/2458398/NeoStrata is rolling out the NeoStrata ProSystem Retinol Peel, the first retinol peel for the brand. The peel contains 3% Retinol plus Retinol Boosting Complex to exfoliate and improve the appearance of fine lines and wrinkles, help reduce acne,
- FDA Clears Merz Aesthetics' Cellfina System for Long-Term Improvement of Cellulitehttps://practicaldermatology.com/news/fda-clears-merz-aesthetics-cellfina-system-for-long-term-improvement-of-cellulite/2458399/The FDA has cleared the Cellfina System from Merz Aesthetics, a division of Merz North America, for the long-term improvement in the appearance of cellulite on the buttocks and thighs of adult females with no loss of benefit for up to 3 years. Cellfina is the only FDA-cleared minimally in
- Encore Dermatology Introduces HylatopicPlus® Lotionhttps://practicaldermatology.com/news/encore-dermatology-introduces-hylatopicplus-lotion/2458402/Encore Dermatology, Inc. is expanding its line to with HylatopicPlus® Lotion in a 14 oz. bottle with pump dispenser. The Rx product relieves the burning, itching and pain experienced with various types of skin conditions, includi
- Aesthetics Industry Veteran Pat Altavilla Joins Suneva Medical As Vice President Of Marketinghttps://practicaldermatology.com/news/aesthetics-industry-veteran-pat-altavilla-joins-suneva-medical-as-vice-president-of-marketing/2458410/Suneva Medical, Inc., appointed Pat Altavilla as vice president of marketing. With more than 30 years of experience in the aesthetics and medical fields, Altavilla will oversee all marketing aspects for the company, further fortifying the brand's strong le
- Phase 3 Study: Yervoy Improves Overall Survival in Fully Resected Stage III Melanoma Patientshttps://practicaldermatology.com/news/phase-3-study-yervoy-improves-overall-survival-in-fully-resected-stage-iii-melanoma-patients/2458408/Yervoy 10 mg/kg demonstrated superiority versus placebo on all survival endpoints in the Phase 3 trial CA184-029 (EORTC 18071) evaluating stage III melanoma patients who are at high risk of recurrence following complete surgical resection, according to Bristol-Myers Squibb Company. In the study,
- Opdivo Stabilized Patient-reported Outcomes in Previously Treated Recurrent or Metastatic SCC of Head and Neckhttps://practicaldermatology.com/news/opdivo-stabilized-patient-reported-outcomes-in-previously-treated-recurrent-or-metastatic-scc-of-head-and-neck/2458409/Bristol-Myers Squibb Company reported new patient-reported quality-of-life data from an exploratory endpoint in the pivotal Phase 3 CheckMate -141 trial evaluating Opdivo in patients with recurrent or metastatic squamous cell carcinoma of the head and neck after platinum therapy compared to inves